# A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv

Source: https://onco.cc/trials/nct06780137/  
OnCo record `nct06780137` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ifinatamab deruxtecan, Durvalumab in small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) is a phase 1/2 interventional study registered as NCT06780137 by Merck Sharp & Dohme LLC, with 327 participants planned, started 2025-02-27 and due to reach its primary completion in 2029-04-27. Interventions recorded: Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06780137
- Phase: 1/2
- Setting: A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 327

## Sources

- ClinicalTrials.gov NCT06780137: https://clinicaltrials.gov/study/NCT06780137

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06780137.json